TokenPost·
Novartis Presents Two-Year Ianalumab Results in Sjögren’s Disease
Results from the NEPTUNUS extension study showed further improvements in disease activity.
More news
- Crypto BriefingCoinShares survey: Bitcoin leads growth outlook as Ethereum sentiment improves
- TokenPostPoland's Sejm Passes Bill for Crypto Freezes Before Court Review
- TokenPostAnthropic Is Setting Aside Up to 20% of IPO Shares for Retail
- TokenPostSEC Reports 348 Enforcement Actions for Fiscal 2026, Down From 456
- The DefiantNomura Explores Laser Digital Sale, Bloomberg Reports
- Crypto BriefingTexas bill would let cities and counties invest up to $10M each in Bitcoin